Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with β1 integrins

Journal of Cell Science

Volumn 121, Issue 22, 2008, Pages 3747-3758

  Tang, Chi Hui ^a   Hill, Maria L ^a   Brumwell, Alexis N ^a   Chapman, Harold A ^a   Wei, Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Integrin; Lung cancer; Signaling; Urokinase; Urokinase receptor

Indexed keywords

ALPHAVBETA5 INTEGRIN; BETA1 INTEGRIN; CAVEOLIN; CD51 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT1 PROTEIN; UROKINASE; UROKINASE RECEPTOR; VERY LATE ACTIVATION ANTIGEN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CELL ADHESION; CELL MIGRATION; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANTIGENS, CD29; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; POINT MUTATION; PROTEIN BINDING; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 59549087883     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.029769     Document Type: Article

References (53)

1. Adachi, T., Kar, S., Wang, M. and Carr, B. I. (2002). Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J. Cell Physiol. 192, 151-159.
2. Aguirre Ghiso, J. A., Kovalski, K. and Ossowski, L. (1999). Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104.
3. Ahmed, N., Oliva, K., Wang, Y., Quinn, M. and Rice, G. (2003). Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br. J. Cancer 89, 374-384.
4. Blasi, F. and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol. 3, 932-943.
5. Carriero, M. V., Del Vecchio, S., Capozzoli, M., Franco, P., Fontana, L., Zannetti, A., Botti, G., D'Aiuto, G., Salvatore, M. and Stoppelli, M. P. (1999). Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59, 5307-5314.
6. Chaurasia, P., Aguirre-Ghiso, J. A., Liang, O. D., Gardsvoll, H., Ploug, M. and Ossowski, L. (2006). A region in urokinase plasminogen receptor domain III controlling a functional association with {alpha}5beta1 integrin and tumor growth. J. Biol. Chem. 281, 14852-14863.
7. Chen, X., Su, Y., Fingleton, B., Acuff, H., Matrisian, L. M., Zent, R. and Pozzi, A. (2005). An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice. Clin. Exp. Metastasis 22, 185-193.
8. Czekay, R. P., Aertgeerts, K., Curriden, S. A. and Loskutoff, D. J. (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 160, 781-791.
9. Dano, K., Romer, J., Nielsen, B. S., Bjorn, S., Pyke, C., Rygaard, J. and Lund, L. R. (1999). Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107, 120-127.
10. Degryse, B., Resnati, M., Czekay, R. P., Loskutoff, D. J. and Blasi, F. (2005). Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 280, 24792-24803.
11. Dumler, I., Weis, A., Mayboroda, O. A., Maasch, C., Jerke, U., Haller, H. and Gulba, D. C. (1998). The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273, 315-321.
12. Erman, M., Grunenwald, D., Penault-Llorca, F., Grenier, J., Besse, B., Validire, P., Morat, L., Girard, P., Le Chevalier, T., Sabatier, L. et al. (2005). Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 47, 315-323.
13. Franco, P., Vocca, I., Carriero, M. V., Alfano, D., Cito, L., Longanesi-Cattani, I., Grieco, P., Ossowski, L. and Stoppelli, M. P. (2006). Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J. Cell Sci. 119, 3424-3434.
14. Galaria, I. I., Nicholl, S. M., Roztocil, E. and Davies, M. G. (2005). Urokinase-induced smooth muscle cell migration requires PI3-K and Akt activation. J. Surg. Res. 127, 46-52.
15. Gargiulo, L., Longanesi-Cattani, I., Bifulco, K., Franco, P., Raiola, R., Campiglia, P., Grieco, P., Peluso, G., Stoppelli, M. P. and Carriero, M. V. (2005). Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J. Biol. Chem. 280, 25225-25232.
16. Ghosh, S., Johnson, J. J., Sen, R., Mukhopadhyay, S., Liu, Y., Zhang, F., Wei, Y., Chapman, H. A. and Stack, M. S. (2006). Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J. Biol. Chem. 281, 13021-13029.
17. He, C., He, P., Liu, L. P. and Zhu, Y. S. (2001). Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells. J. Cancer Res. Clin. Oncol. 127, 180-186.
18. Inuzuka, K., Ogata, Y., Nagase, H. and Shirouzu, K. (2000). Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J. Surg. Res. 93, 211-218.
19. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M. J. (2007). Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66.
20. Jo, M., Thomas, K. S., Marozkina, N., Amin, T. J., Silva, C. M., Parsons, S. J. and Gonias, S. L. (2005). Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 280, 17449-17457.
21. Lakka, S. S., Rajagopal, R., Rajan, M. K., Mohan, P. M., Adachi, Y., Dinh, D. H., Olivero, W. C., Gujrati, M., Ali-Osman, F., Roth, J. A. et al. (2001). Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. Clin. Cancer Res. 7, 1087-1093.
22. Leinonen, T., Pirinen, R., Bohm, J., Johansson, R., Ropponen, K. and Kosma, V. M. (2006). Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer: relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 51, 313-321.
23. Lin, T. S., Chiou, S. H., Wang, L. S., Huang, H. H., Chiang, S. F., Shih, A. Y., Chen, Y. L., Chen, C. Y., Hsu, C. P., Hsu, N. Y. et al. (2004). Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol. Rep. 12, 717-723.
24. Liu, G., Shuman, M. A. and Cohen, R. L. (1995). Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60, 501-506.
25. Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O. and Sidenius, N. (2007). uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 177, 927-939.
26. Mazzieri, R., D'Alessio, S., Kenmoe, R. K., Ossowski, L. and Blasi, F. (2006). An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17, 367-378.
27. Murphy, G. and Gavrilovic, J. (1999). Proteolysis and cell migration: creating a path? Curr. Opin. Cell Biol. 11, 614-621.
28. Nguyen, D. H., Hussaini, I. M. and Gonias, S. L. (1998). Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273, 8502-8507.
29. Nguyen, D. H., Catling, A. D., Webb, D. J., Sankovic, M., Walker, L. A., Somlyo, A. V., Weber, M. J. and Gonias, S. L. (1999). Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell Biol. 146, 149-164.
30. Offersen, B. V., Pfeiffer, P., Andreasen, P. and Overgaard, J. (2007). Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 56, 43-50.
31. Onn, A., Isobe, T., Itasaka, S., Wu, W., O'Reilly, M. S., Ki Hong, W., Fidler, I. J. and Herbst, R. S. (2003). Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin. Cancer Res. 9, 5532-5539.
32. Ploug, M., Ronne, E., Behrendt, N., Jensen, A. L., Blasi, F. and Dano, K. (1991). Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266, 1926-1933.
33. Pulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M. and Rao, J. S. (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280, 36529-36540.
34. Rao, J. S., Gondi, C., Chetty, C., Chittivelu, S., Joseph, P. A. and Lakka, S. S. (2005). Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol. Cancer Ther. 4, 1399-1408.
35. Saldanha, R. G., Molloy, M. P., Bdeir, K., Cines, D. B., Song, X., Uitto, P. M., Weinreb, P. H., Violette, S. M. and Baker, M. S. (2007). Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. J. Proteome Res. 6, 1016-1028.
36. Shetty, S., Rao, G. N., Cines, D. B. and Bdeir, K. (2006). Urokinase induces activation of STAT3 in lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 291, L772-L780.
37. Simon, D. I., Rao, N. K., Xu, H., Wei, Y., Majdic, O., Ronne, E., Kobzik, L. and Chapman, H. A. (1996). Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88, 3185-3194.
38. Sung, S. Y., Hsieh, C. L., Wu, D., Chung, L. W. and Johnstone, P. A. (2007). Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr. Probl. Cancer 31, 36-100.
39. Takenaka, K., Shibuya, M., Takeda, Y., Hibino, S., Gemma, A., Ono, Y. and Kudoh, S. (2000). Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int. J. Oncol. 17, 1187-1194.
40. Tarui, T., Akakura, N., Majumdar, M., Andronicos, N., Takagi, J., Mazar, A. P., Bdeir, K., Kuo, A., Yarovoi, S. V., Cines, D. B. et al. (2006). Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost. 95, 524-534.
41. Vial, E., Sahai, E. and Marshall, C. J. (2003). ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4, 67-79.
42. Wang, H., Fu, W., Im, J. H., Zhou, Z., Santoro, S. A., Iyer, V., DiPersio, C. M., Yu, Q. C., Quaranta, V., Al-Mehdi, A. et al. (2004). Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J. Cell Biol. 164, 935-941.
43. Wei, C., Moller, C. C., Altintas, M. M., Li, J., Schwarz, K., Zacchigna, S., Xie, L., Henger, A., Schmid, H., Rastaldi, M. P. et al. (2008). Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55-63.
44. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S. and Chapman, H. A. (1994). Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269, 32380-32388.
45. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V. and Chapman, H. A. (1996). Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
46. Wei, Y., Eble, J. A., Wang, Z., Kreidberg, J. A. and Chapman, H. A. (2001). Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 12, 2975-2986.
47. Wei, Y., Czekay, R. P., Robillard, L., Kugler, M. C., Zhang, F., Kim, K. K., Xiong, J. P., Humphries, M. J. and Chapman, H. A. (2005). Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168, 501-511.
48. Wei, Y., Tang, C. H., Kim, Y., Robillard, L., Zhang, F., Kugler, M. C. and Chapman, H. A. (2007). Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 282, 3929-3939.
49. Wu, Y., Rizzo, V., Liu, Y., Sainz, I. M., Schmuckler, N. G. and Colman, R. W. (2007). Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 27, 1968-1975.
50. Xue, W., Mizukami, I., Todd, R. F., 3rd and Petty, H. R. (1997). Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57, 1682-1689.
51. Yebra, M., Goretzki, L., Pfeifer, M. and Mueller, B. M. (1999). Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp. Cell Res. 250, 231-240.
52. Zhang, F., Tom, C. C., Kugler, M. C., Ching, T. T., Kreidberg, J. A., Wei, Y. and Chapman, H. A. (2003). Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J. Cell Biol. 163, 177-188.
53. Zhao, Y. L., Piao, C. Q. and Hei, T. K. (2002). Overexpression of Betaig-h3 gene downregulates integrin alpha5beta1 and suppresses tumorigenicity in radiation-induced tumorigenic human bronchial epithelial cells. Br. J. Cancer 86, 1923-1928.